Biorestorative Therapies Inc (BRTX)

$1.53

+0.02

(+1.32%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $1.51
    $1.57
    $1.53
    downward going graph

    1.14%

    Downside

    Day's Volatility :3.35%

    Upside

    2.24%

    downward going graph
  • $1.03
    $3.67
    $1.53
    downward going graph

    32.68%

    Downside

    52 Weeks Volatility :71.93%

    Upside

    58.31%

    downward going graph

Returns

PeriodBiorestorative Therapies IncIndex (Russel 2000)
3 Months
31.9%
0.0%
6 Months
15.91%
0.0%
1 Year
-19.05%
0.0%
3 Years
-78.21%
-22.3%

Highlights

Market Capitalization
10.7M
Book Value
$1.56
Earnings Per Share (EPS)
-0.86
PEG Ratio
0.0
Wall Street Target Price
12.0
Profit Margin
0.0%
Operating Margin TTM
-2770.83%
Return On Assets TTM
-54.83%
Return On Equity TTM
-32.65%
Revenue TTM
174.1K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
38.1%
Gross Profit TTM
119.8K
EBITDA
-12.7M
Diluted Eps TTM
-0.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.63
EPS Estimate Next Year
-1.68
EPS Estimate Current Quarter
-0.56
EPS Estimate Next Quarter
-0.63

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Biorestorative Therapies Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 684.31%

Current $1.53
Target $12.00

Company Financials

FY18Y/Y Change
Revenue
111.0K
↑ 37.04%
Net Income
-12.5M
↑ 32.54%
Net Profit Margin
-11.3K%
↑ 382.77%
FY19Y/Y Change
Revenue
130.0K
↑ 17.12%
Net Income
-14.6M
↑ 17.02%
Net Profit Margin
-11.3K%
↑ 9.69%
FY20Y/Y Change
Revenue
77.0K
↓ 40.77%
Net Income
-12.3M
↓ 16.34%
Net Profit Margin
-15.9K%
↓ 4647.56%
FY21Y/Y Change
Revenue
46.0K
↓ 40.26%
Net Income
-29.9M
↑ 144.3%
Net Profit Margin
-65.1K%
↓ 49168.75%
FY22Y/Y Change
Revenue
119.8K
↑ 160.43%
Net Income
-18.0M
↓ 39.83%
Net Profit Margin
-15.0K%
↑ 50045.93%
FY23Y/Y Change
Revenue
145.8K
↑ 21.7%
Net Income
-10.4M
↓ 42.17%
Net Profit Margin
-7.1K%
↑ 7892.79%
Q4 FY22Q/Q Change
Revenue
3.7K
↓ 87.24%
Net Income
-3.8M
↓ 18.71%
Net Profit Margin
-103.3K%
↓ 87088.33%
Q1 FY23Q/Q Change
Revenue
31.3K
↑ 745.95%
Net Income
-5.6M
↑ 46.71%
Net Profit Margin
-17.9K%
↑ 85386.42%
Q2 FY23Q/Q Change
Revenue
64.5K
↑ 106.07%
Net Income
-3.0M
↓ 46.85%
Net Profit Margin
-4.6K%
↑ 13294.52%
Q3 FY23Q/Q Change
Revenue
30.7K
↓ 52.4%
Net Income
-83.3K
↓ 97.2%
Net Profit Margin
-271.44%
↑ 4349.57%
Q1 FY24Q/Q Change
Revenue
35.0K
↑ 14.01%
Net Income
-2.2M
↑ 2567.92%
Net Profit Margin
-6.4K%
↓ 6080.72%
Q2 FY24Q/Q Change
Revenue
89.1K
↑ 154.57%
Net Income
-4.0M
↑ 81.2%
Net Profit Margin
-4.5K%
↑ 1830.77%
FY18Y/Y Change
Total Assets
1.2M
↓ 32.2%
Total Liabilities
9.8M
↑ 14.41%
FY19Y/Y Change
Total Assets
1.5M
↑ 22.97%
Total Liabilities
14.2M
↑ 44.84%
FY20Y/Y Change
Total Assets
4.3M
↑ 196.46%
Total Liabilities
5.7M
↓ 60.13%
FY21Y/Y Change
Total Assets
22.5M
↑ 416.52%
Total Liabilities
856.5K
↓ 84.92%
FY22Y/Y Change
Total Assets
16.4M
↓ 26.81%
Total Liabilities
602.6K
↓ 29.64%
FY23Y/Y Change
Total Assets
12.6M
↓ 23.26%
Total Liabilities
2.6M
↑ 332.67%
Q1 FY23Q/Q Change
Total Assets
14.1M
↓ 14.32%
Total Liabilities
593.9K
↓ 1.44%
Q2 FY23Q/Q Change
Total Assets
13.3M
↓ 5.54%
Total Liabilities
896.4K
↑ 50.93%
Q3 FY23Q/Q Change
Total Assets
13.8M
↑ 3.77%
Total Liabilities
975.0K
↑ 8.77%
Q1 FY24Q/Q Change
Total Assets
18.0M
-
Total Liabilities
3.4M
↑ 32.25%
Q2 FY24Q/Q Change
Total Assets
16.1M
↓ 10.21%
Total Liabilities
5.3M
↑ 54.28%
FY18Y/Y Change
Operating Cash Flow
-5.1M
↑ 32.46%
Investing Cash Flow
-12.9K
↑ 255.79%
Financing Cash Flow
4.8M
↑ 11.83%
FY19Y/Y Change
Operating Cash Flow
-6.9M
↑ 35.54%
Investing Cash Flow
-35.6K
↑ 176.87%
Financing Cash Flow
6.8M
↑ 42.97%
FY20Y/Y Change
Operating Cash Flow
-2.0M
↓ 71.61%
Investing Cash Flow
-35.6K
↑ 0.0%
Financing Cash Flow
5.0M
↓ 26.49%
FY21Y/Y Change
Operating Cash Flow
-3.3M
↑ 69.52%
Investing Cash Flow
-30.7K
↓ 13.96%
Financing Cash Flow
21.3M
↑ 324.15%
FY22Y/Y Change
Operating Cash Flow
-5.9M
↑ 76.3%
Investing Cash Flow
-13.5M
↑ 43866.95%
Financing Cash Flow
21.1M
↓ 1.17%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.6M
↑ 8.38%
Investing Cash Flow
-3.3M
↓ 66.46%
Financing Cash Flow
411.7K
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.3M
↑ 49.28%
Investing Cash Flow
665.8K
↓ 120.04%
Financing Cash Flow
411.7K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-1.1M
↓ 51.88%
Investing Cash Flow
665.8K
↑ 0.0%
Financing Cash Flow
411.7K
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Biorestorative Therapies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biorestorative Therapies Inc
Biorestorative Therapies Inc
15.91%
15.91%
-19.05%
-78.21%
-78.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biorestorative Therapies Inc
Biorestorative Therapies Inc
NA
NA
0.0
-1.63
-0.33
-0.55
NA
1.56
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biorestorative Therapies Inc
Biorestorative Therapies Inc
Buy
$10.7M
-78.21%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Biorestorative Therapies Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 30.7K → 89.1K (in $), with an average increase of 36.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -83.33K → -4.02M (in $), with an average decrease of 1324.6% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 56.1%

Institutional Holdings

  • Sabby Management LLC

    2.44%

  • StoneX Group Inc

    0.72%

  • Geode Capital Management, LLC

    0.58%

  • Wealth Alliance, LLC

    0.58%

  • Renaissance Technologies Corp

    0.36%

  • Vanguard Group Inc

    0.30%

Company Information

biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas

Organization
Biorestorative Therapies Inc
Employees
11
CEO
Mr. Lance Alstodt
Industry
Biotechnology

Discover More

FAQs